Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first ...

(NASDAQ:KYMR) is among the best biotech stocks. TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone ...

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified ...

Baker Bros. Advisors reported a buy of 2,005,813 Kymera Therapeutics (NASDAQ:KYMR) shares in its February 17, 2026, SEC filing, an estimated $135.45 million trade based on quarterly average pricing.

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track ...

Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings ...

Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...